GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction

A novel disialoganglioside 2 (GD2)-specific chimeric antigen receptor (CAR)-modified T cell therapy against retinoblastoma (RB) were generated. GD2-CAR consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody, hu3F8, that is linked with the cytoplasmic signaling domains...

Descripción completa

Detalles Bibliográficos
Autores principales: Sujjitjoon, Jatuporn, Sayour, Elias, Tsao, Shih-Ting, Uiprasertkul, Mongkol, Sanpakit, Kleebsabai, Buaboonnam, Jassada, Yenchitsomanus, Pa-thai, Atchaneeyasakul, La-ongsri, Chang, Lung-Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745061/
https://www.ncbi.nlm.nih.gov/pubmed/33321428
http://dx.doi.org/10.1016/j.tranon.2020.100971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745061/
https://www.ncbi.nlm.nih.gov/pubmed/33321428
http://dx.doi.org/10.1016/j.tranon.2020.100971

Ejemplares similares